Immunotherapy combo may boost liver cancer ablation outcomes
NCT ID NCT06045975
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination, then undergo ablation, followed by 11 monthly infusions of durvalumab alone. The main goal is to see how long patients stay free of local recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab and Tremelimumab (immunotherapy drugs)
What this could lead to
If it works, this could offer a new way to reduce the chance of liver cancer coming back after ablation treatment.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospitl Avicenne
Bobigny, 93000, France